Alnylam Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$417.5M
Lead Investor(s):Barclays Capital Inc

Estimated Revenue & Financials

  • Alnylam Pharmaceuticals's estimated annual revenue is currently $74.9M per year.
  • Alnylam Pharmaceuticals received $445.6M in venture funding in January 2019.
  • Alnylam Pharmaceuticals's estimated revenue per employee is $58,659
  • Alnylam Pharmaceuticals's total funding is $417.5M.

Employee Data

  • Alnylam Pharmaceuticals has 1277 Employees.
  • Alnylam Pharmaceuticals grew their employee count by 31% last year.
  • Alnylam Pharmaceuticals currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ohana Bioscienc...
Compass Therape...
Cell Signaling ...
Momenta Pharmac...
Hamilton Storag...
Alnylam Pharmac...
Missing a competitor? Contribute!?

To those who say impossible, impractical, unrealistic, we say: CHALLENGE ACCEPTED. We are developing an innovative, entirely new class of medicines called RNAi therapeutics to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology - the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today's medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn't have to wait for hope. Alnylam is turning scientific possibility into reality - in August of 2018, the U.S. FDA approval of our first product ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. Our robust RNAi discovery platform and deep pipeline of investigational medicines includes three programs in late-stage clinical development and multiple programs in early-stage clinical development. We are a global and diverse company of more than 850 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Boston Globe Top Place to Work three years in a row! We are based in Cambridge, U.S., with offices in Zug, Switzerland, and Maidenhead, UK, and operations and employees across the U.S. and throughout Europe and Asia. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam) and YouTube. You can also sign up for email updates here:



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Executive Contacts

Noriyuki KawahataAssociate Director, Program And Alliance Management
Lauren PalazolaCase Manager
Renae GoodridgeManager, Case
Wendell DavisSenior Director, Pathology
Sara WalshSenior Manager, Meeting Planning
Donna BeccariaVP, Enterprise Learning
Leah El-SerganiSenior Manager, Business Planning
Ally HeAssociate Director, Biostatistics
Nicholas ParkSenior Manager, Accounting
Akshay VaishnawEvp R&d, Chief Medical Officer

Alnylam Pharmaceuticals News

09/03/2019 - Alnylam Pharmaceuticals Provides Perspective on Positive ...

BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today provided perspective on ...

09/08/2019 - Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare ...

09/03/2019 - Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded to “Hold” at BidaskClub

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note ...

Alnylam Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2003-07-09$24.6MLead Investor: MultiArticle
2003-09-10$UndisclosedStrategic InvestmenMerckArticle
2006-12-18$101.0MUndisclosedAmerica Securities LLCArticle
2013-01-16$125.0MUndisclosedJP Morgan Securities LLC, Morgan Stanley & Co LLCArticle
2015-01-22$517.5MUndisclosedJ.P. Morgan Securities LLCArticle
2017-05-25$413.2MUndisclosedBarclays Capital IncArticle
2017-11-14$675.0MUndisclosedGoldman Sachs & Co. LLCArticle
2019-01-16$445.6MUndisclosedBarclays Capital IncArticle

Alnylam Pharmaceuticals Executive Hires

2002-12-05John M. MaraganoreCEO/PresidentArticle
2003-04-17Victor E KotelianskiVP Research/OpersArticle
2003-07-01Thomas R. UlichSVP R/DArticle
2003-07-29Vincent MilesSVP Business DevelopmentArticle
2004-06-25Patricia AllenVP FinanceArticle
2006-02-09Akshay VaishnawVice President Clinical ResearchArticle
2006-06-15Sara NochurVP Regulatory AffairsArticle
2007-12-17Barry GreenePres/COOArticle
2008-10-02John A. SchmidtChief Scientific OfficerArticle
2010-06-03Laurence ReidSVP/Chief Business OfficerArticle
2011-03-04Patricia AllenVP Finance/TreasurerArticle
2011-06-14Akshay K VaishnawChief Medical OfficerArticle
2012-06-28Akshay VaishnawEVP/Chief Medical OfficerArticle
2014-09-16Karen AndersonSVP/Chief Human Resources OfficerArticle
2014-10-30Pushkal GargSVP Clinical DevelopmentArticle
2015-06-09David-AlexandreSVP/Chief Business OfficerArticle
2016-09-20Yvonne GreenstreetEVP/Chief Operating OfficerArticle
2017-01-04Pushkal GargChief Medical OfficerArticle
2017-05-10Manmeet Sonichief financial officerArticle
2018-06-21Masako NakamuraSVP Head of AsiaArticle

Alnylam Pharmaceuticals New Location/Offices

2016-04-29Boston, MAArticle

Alnylam Pharmaceuticals Staff Cuts

DateNumber of EmployeesLocationReference
2010-09-2420-30 % JobsArticle
2012-01-2033% JobsArticle
2012-01-2361 JobsArticle